 Nes-Ziona, Israel, Feb. 24, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. ENLV, a clinical-stage immunotherapy company, today announced that it is initiating a plan to increase its manufacturing capacity of AllocetraTM, following the first confirmed coronavirus COVID-19 case in Israel, in preparation for potential requests for treatment of coronavirus COVID-19 patients who are hospitalized with diagnosed organ dysfunctions or failures related to coronavirus. AllocetraTM is an experimental therapy being investigated for treatment of patients with organ failure associated with sepsis, a syndrome whose lethal pathophysiology cytokine storm followed by organ failure is similar to that of the coronavirus COVID-19. Sepsis is the 3rd leading cause of mortality in the United States. 